IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9815846 B1

PDFFull Text
Date of Patent:
Nov. 14, 2017

Filed:

Mar. 23, 2015

Trka kinase inhibitors, compositions and methods thereof

Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Msd R & D (China) Co., Ltd., Shanghai, CN;

Inventors:

Helen Mitchell, Richboro, PA (US);

Mark E. Fraley, North Wales, PA (US);

Andrew J. Cooke, West Point, PA (US);

Craig A. Stump, West Point, PA (US);

Yi-Heng Chen, Whippany, NJ (US);

Xu-Fang Zhang, Dresher, PA (US);

Casey C. McComas, Phoenixville, PA (US);

Kathy Schirripa, Quakertown, PA (US);

Melody McWherter, Boyertown, PA (US);

Swati P. Mercer, Philadelphia, PA (US);

Kerim Babaoglu, Lansdale, PA (US);

Dongfang Meng, Morganville, NJ (US);

Jane Wu, Marlboro, NJ (US);

Ping Liu, Westfield, NJ (US);

Harold B. Wood, Westfield, NJ (US);

Jianming Bao, Shanghai, CN;

Chun Sing Li, Shanghai, CN;

Qinghua Mao, Shanghai, CN;

Zhiqi Qi, Shanghai, CN;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Sylvia A. Ayler

John C. Todaro

Primary Examiner:

Golam M M Shameem

Int. Cl.
CPC ...
C07D 491/107 (2006.01); C07C 233/66 (2006.01); C07D 213/75 (2006.01); C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 417/12 (2006.01); C07D 239/42 (2006.01); C07D 401/04 (2006.01); C07D 413/12 (2006.01); C07D 417/14 (2006.01); C07D 401/14 (2006.01); C07D 405/12 (2006.01); C07D 413/14 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 471/04 (2006.01); C07D 401/06 (2006.01); C07D 413/06 (2006.01); C07D 403/06 (2006.01);
U.S. Cl.
CPC ...
C07D 491/107 (2013.01); C07C 233/66 (2013.01); C07D 213/75 (2013.01); C07D 239/42 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01);
Abstract

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

Find Patent Forward Citations

Loading…